Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
Follow BNTX by emailGet an email when BNTX pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about BNTX, unsubscribe in one click. Privacy
📣 What BNTX Says Is Next
in 2026 · “The timing of this readout is no longer expected in 2026 due to an increase in the enrollment target of the trial. 8.”
Company press release, Aug 4, 2026 · SEC filing
in 2026 · “The timing of this readout is no longer expected in 2026 due to data maturity. 7.”
Company press release, Aug 4, 2026 · SEC filing
in 2027 · “Data expected at WCLC 2026 Phase 2 final analysis expected in 2027 Primary completion date expected in 2031 Phase 3 interim analysis expected in 2026 Individualized Immunotherapy – iNeST1 Off-the-shelf Immunotherapy – FixVac Multiple Milestones Achieved in 2026 and Upcoming Catalysts 17 Some data readouts may be event-driven and subject to change based on actual event accrual rates or publication strategy.”
Company press release, Aug 4, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for BNTX and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.